ALXO - Alx Oncology Holdings  logo

ALXO

Alx Oncology Holdings 

Rev —top 1%5Y
Hold

ALX Oncology Holdings develops immuno-oncology therapies for cancer patients, with a focus on Evorpacept, a CD47-blocking therapeutic biologic. The company collaborates on various combination therapies for treating multiple cancer types in clinical trials.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $30today

Score Overview

1 Year
Score
Net Growth20.46%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth3.08%
Net Trend60%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-76.85%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency

See the full market ranking →

Alx Oncology Holdings  fundamental performance

Across Alx Oncology Holdings 's full reported history, from 2020 to 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 45M to -$ 101M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.01
1 Year2025-08-12
$ 0.62226.78%
5 Years2021-08-12
$ 66.41-96.97%
All Time2020-07-17
$ 30.00-93.30%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 80M$ 138M
2025$ 0.00-$ 101M$ 44M
2024$ 0.00-$ 134M$ 127M
2023$ 0.00-$ 160M$ 182M
2022$ 0.00-$ 123M$ 266M
2021$ 0.00-$ 83M$ 363M
IPO2020$ 1M-$ 45M$ 434M

Explore beyond ALXO

You're looking at Alx Oncology Holdings . Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies